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Abstract
Background: Anxiety in patients with chronic obstructive pulmonary disease (COPD) is associated with self-
reported disability. The purpose of this study is to determine whether there is an association between anxiety and
functional measures, quality of life and dyspnea.
Methods: Data from 1828 patients with moderate to severe emphysema enrolled in the National Emphysema
Treatment Trial (NETT), collected prior to rehabilitation and randomization, were used in linear regression models to
test the association between anxiety symptoms, measured by the Spielberger State Trait Anxiety Inventory (STAI)
and: (a) six-minute walk distance test (6 MWD), (b) cycle ergometry peak workload, (c) St. Georges Respiratory
Questionnaire (SRGQ), and (d) UCSD Shortness of Breath Questionnaire (SOBQ), after controlling for potential
confounders including age, gender, FEV1 (% predicted), DLCO (% predicted), and the Beck Depression Inventory
(BDI).
Results: Anxiety was significantly associated with worse functional capacity [6 MWD (B = -0.944, p < .001),
ergometry peak workload (B = -.087, p = .04)], quality of life (B = .172, p < .001) and shortness of breath (B = .180,
p < .001). Regression coefficients show that a 10 point increase in anxiety score is associated with a mean decrease
in 6 MWD of 9 meters, a 1 Watt decrease in peak exercise workload, and an increase of almost 2 points on both
the SGRQ and SOBQ.
Conclusion: In clinically stable patients with moderate to severe emphysema, anxiety is associated with worse
exercise performance, quality of life and shortness of breath, after accounting for the influence of demographic
and physiologic factors known to affect these outcomes.
Trail Registration: ClinicalTrials.gov NCT00000606
Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of disability and death. Disability, func-
tional limitations and decreased quality of life in patients
with COPD are correlated with objective physiologic
measures of disease severity [1-3]. However, a large pro-
portion of the variance in functional status and quality
of life associated with COPD is not explained by mea-
sures of pulmonary physiology. Psychological factors
may play in important role in determining the impact of
COPD on patient functioning. For example, anxiety in
patients with COPD has been associated with decreased
quality of life, more severe dyspnea, greater disability,
and impaired functional status [4,5] even after control-
ling for lung function and the presence of other chronic
diseases [6,7]. Anxiety is also a significant predictor of
the frequency of hospitalizations for acute exacerbations
of COPD [8].
Anxiety is a major clinical problem in patients with
COPD. The prevalence of clinical anxiety disorders in
patients with COPD is substantially higher than in the
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general public. Anxiety symptoms are very common in
patients with COPD. In previously published studies 10-
80% of patients endorsed anxiety symptoms [1,7,9-12],
exceeding that for patients with other chronic medical
conditions such as heart disease, renal disease, AIDS
and cancer [13,14]. Estimates for specific anxiety disor-
ders range from a 10-32%, a 3- to 10-fold increase in
COPD compared to the general population. The most
common anxiety disorders diagnosed with COPD are
generalized anxiety disorder and panic disorder, which
may occur in as many as one-third of COPD patients
[15-17]. Defining the contribution of anxiety to func-
tional impairment in COPD is a first step in determin-
ing the potential for interventions to combat anxiety to
improve functional status.
Most previous studies of the impact of anxiety on
patients with COPD have relied on patient self-report
measures of functioning [4,6,7]. In these studies self-
report biases may confound the true association
between psychological and physical health [18]. Investi-
gations that have included objective measures of func-
tioning (e.g., 6-minute walk distance test (6 MWD))
have been limited by small sample size, or have included
only patients selected for high levels of anxiety and
depression [5,9].
In the current study, we hypothesized that anxiety
would be associated with worse functional performance
(6 MWD; maximal exercise capacity), health-related qual-
ity of life (SGRQ), and dyspnea (SOBQ), after controlling
for the effects of potential confounders including age,
pulmonary function and depression. We used data from
a carefully characterized large group of patients with
severe emphysema who were evaluated for the National
Emphysema Treatment Trial (NETT). We also examined
whether sex differences existed in the relationship
between anxiety symptoms and outcomes variables
(6 MWD, maximal exercise capacity, SGRQ, SOBQ).
Methods
Study group
Ethics committee approval for the NETT was obtained
from the Institutional Review Boards of all participating
sites. Procedures for recruitment, screening, determina-
tion of eligibility, and assessments for the NETT are
described in detail elsewhere [19,20]. Briefly, 3777
patients were screened for the NETT from 1998 to
2002. Patients were included if they had moderate to
severe emphysema, had been nonsmokers for at least 6
months, and did not have clinically significant comorbid
conditions or circumstances that placed them at high
risk for perioperative morbidity or mortality or made it
unlikely that they would complete the trial. In order to
maximize generalizability and sample heterogeneity,
patients were included in the analyses if they had all of
the required data from the initial screening assessment,
prior to the start of the pre-randomization rehabilitation
program. 1828 patients met these criteria. A total of 1218
patients went on to randomization to receive either lung
volume reduction surgery or continued regular medical
treatment. Patients failed to reach randomization for a
number of reasons, for example failure to complete reha-
bilitation program and all postrehabilitation and randomi-
zation assessments, failure to obtain final approval for
surgery just prior to randomization, and other new onset
complications that met study exclusion criteria. Although
no differences between randomized and non-randomized
patients were expected in our analyses, in order to allow
comparison with a number of other reports that are
based on data only from randomized NETT subjects, our
data analyses were also repeated for randomized patients
with complete data from the initial screening assessment
on all variables analyzed (n = 1154).
Demographic and questionnaire measures
Demographics and self-report measures were collected
using standardized instruments including:
Spielberger State Trait Anxiety Inventory (STAI; [21])
The STAI is a 40-item self-report measure of enduring
(trait) and transient (state) anxiety symptoms. Respon-
dents rate how statements reflect how they generally
feel on a 4-point scale. STAI state and trait scores range
from 20-80. State anxiety is defined as unpleasant emo-
tional arousal, characterized by feelings of tension and
apprehension, and heightened autonomic nervous sys-
tem activity, while trait anxiety measures a stable ten-
dency to respond with state anxiety. The state anxiety
scale of the questionnaire was chosen for our analyses
in order to more closely match the time frame refer-
enced by most of our other questionnaire measures (i.e.,
current, versus past or typical, functioning). In addition
the state anxiety measurement has been shown to be
more valid than that of trait anxiety [22].
Beck Depression Inventory (BDI;[23])
The BDI is a 21 item self-report measure of symptoms
of depression. Respondents choose statements that
reflect how they have felt over the past 2 weeks. The
BDI contains 13 items assessing cognitive-mood depres-
sive symptoms (e.g., sadness, guilt) and 8 items that
assess physical-performance symptoms of depression
(e.g., fatigue, weight loss, physical health worries).
St. Georges Respiratory Questionnaire (SGRQ;[24])
The SGRQ is a 60-item-disease specific instrument
developed for use with patients with airflow limitation
and designed to measure health-related quality of life.
We used the full-scale SGRQ score in our analysis.
UCSD Shortness of Breath Questionnaire (UCSD-SOBQ[25])
The UCSD-SOBQ is a 33-item measure of shortness of
breath while performing activities.
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Questionnaires were administered to subjects after
performance of diagnostic testing and determination of
study eligibility.
Physiologic measures
Pulmonary function tests, including spirometry and sin-
gle-breath diffusing capacity (DLCO), were performed in
accordance with American Thoracic Society standards
[26,27]. Spirometry values used in this report (FEV1)
were obtained following bronchodilator (albuterol)
administration. Percent of predicted values were calcu-
lated using normal reference values derived from Crapo
and colleagues [28,29]. The standardized 6 MWD proto-
col has been described in detail elsewhere [30] and pro-
vided maximum distance walked. Maximum exercise
capacity (watts) was measured on an electromagneti-
cally-braked cycle ergometer that increased at a rate of
5 or 10 W per minute after 3 minutes of unloaded ped-
aling while subjects breathed 30 percent oxygen.
Statistical analysis
Descriptive statistics were performed. Analysis of var-
iance was used to compare patients who were versus
were not randomized in the NETT. For categorical vari-
ables a Pearson Chi-square test was performed. Next,
four separate multiple linear regression models were
computed to test the association between state anxiety
and: (a) 6 MWD; (b) maximum exercise capacity; (c) St.
Georges Respiratory Questionnaire total score; and (d)
UCSD Shortness of Breath Questionnaire total score. In
the first regression model, 6 MWD was entered as the
dependent variable. Patient age, gender, FEV1%, DLCO%,
Beck Depression Inventory score and Spielberger State
Anxiety score were entered as the independent variables.
The second through fourth models were identical to the
first, except substituting maximum workload on cardio-
pulmonary exercise test, SGRQ total score, and UCSD
SOBQ total score, respectively, as the dependent vari-
able. In order to test for possible collinearity between
independent variables, eigenvalues of the scaled and
uncentered cross-products matrix, condition indices,
variance-decomposition proportions, variance inflation
factors (VIF) and tolerances were computed for indivi-
dual variables. All statistical analyses were performed
using SPSS statistical software (SPSS, Inc. Chicago, IL,
USA). A probability value of p = .05 was used to deter-
mine statistical significance.
The STAI and BDI are not clinical diagnostic tools.
However there are published cutoff scores for both
instruments to indicate clinically significant symptom
levels. In general population samples, cutoff scores of 19
and 40 are used for the STAI [21] and BDI [23], respec-
tively, to indicate clinically significant symptoms and
likely diagnosis. For the BDI, scores of 10 or above
indicate mild-moderate depressive symptoms. In geria-
tric outpatient populations higher cutoff scores have
been recommended: 22 for the STAI and 44 for the
BDI, based on assessment studies in persons aged 55
and older [31,32]. Questions have also been raised about
the interpretation of specific depression symptoms in
patients with chronic medical illness, including COPD
[33,34]. Because of a concern that the full BDI score
might overestimate depression severity in patients with
more severe emphysema due to overlap between COPD
severity and somatically-focused depression symptoms
on the BDI (e.g., fatigue, weight loss, physical health
worries), we repeated each multiple regression analysis
entering the totals of ‘cognitive-mood’ and ‘physical-per-
formance’ BDI items separately as independent variables.
Results
In general, this study population was elderly and primar-
ily white; approximately two-thirds were male. Subjects’
age range was 28-89 years, with 96% of patients aged 55
or older. Subjects had severe airflow limitation and
impaired diffusing capacity. Compared to published
population norms for the SGRQ (mean = 12.17) [35]
and 6 MWD (mean = 555 meters)[36] in similar age
groups (ages 60-69), subjects in this study showed lower
exercise performance and poorer health-related quality
of life (Table 1).
Subjects showed moderately high levels of baseline
anxiety and depression. Thirty percent of subjects had
state anxiety scores above 40 and twenty percent scored
above 44. Forty-one percent of subjects had a BDI score
of 10 or higher, indicating mild-moderate depressive
symptoms. Eight percent of subjects scored 19 or higher
on the BDI and 4% scored 22 or higher, indicating mod-
erate-severe symptoms. Women had significantly higher
anxiety (36.4 vs. 34.0, p < .001) and depression (10.3 vs.
9.0, p < .001) scores than men. Non-randomized sub-
jects differed significantly from randomized subjects in 6
MWD (337.3 m. vs. 348.0 m., p = .04) and shortness of
breath scores (63.5 vs. 65.5, p = .04), with non-rando-
mized subjects showing greater impairment on both
variables.
Results of multiple linear regression analyses showed
that anxiety was significantly associated with decreased
6 MWD, even after adjusting for patient age, gender,
FEV1 (% predicted), DLCO (% predicted), and depression
(Table 2). Likewise, anxiety was significantly and inver-
sely associated with maximal workload during cardiopul-
monary exercise testing after adjusting for age, gender,
FEV1 %, DLCO %, and depression. Finally, after control-
ling for patient age, gender, FEV1 %, DLCO%, and
depression score, anxiety was also significantly asso-
ciated with SGRQ and UCSD Shortness of Breath Ques-
tionnaire total scores. Regression coefficients from
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models with the BDI mood and physical symptom
scores show that a 10-point increase in anxiety score is
associated with a mean decrease in 6 MWD of 9 meters,
a decrease in maximum exercise workload of almost
1 Watt, and an increase of approximately 2 points on
the SGRQ and the UCSD SOBQ. Collinearity diagnostic
test did not indicate significant collinearity between
independent variables in the regression models (data not
shown). Effects for anxiety were similar when limiting
analyses to only randomized patients, but were not sta-
tistically significant for maximum workload (data not
shown).
Total BDI depression score was also significantly asso-
ciated with 6 MWD (B = -1.12, SE = 0.43, p = .009),
peak workload (B = -0.24, SE = .08, p = .002), SGRQ (B
= .80, SE = 0.05, p < .001) and UCSD Shortness of
Breath Questionnaire (B = 0.950, SE = 0.08, p < .001)
total scores. But, when BDI scores were separated into
‘mood’ and ‘physical’ symptoms scores, physical, but not
mood, symptoms were associated with the dependent
variables in all cases (Table 2).
In separate multivariate regression models predicting
6 MWD, maximum exercise workload, SGRQ, and
UCSD Shortness of Breath Questionnaire total scores, a
significant interaction was found between gender and
anxiety score in predicting SGRQ total score after adjust-
ing for age, FEV1%, DLCO%, and depression score. Anxi-
ety was much more strongly associated with SGRQ for
men (B ± SE = 0.23 ± .04; p < .001; 95% confidence inter-
val [0.16, 0.30]), than for women (B ± SE = 0.09 ± .04;
p = .03; 95% confidence interval [0.01, 0.18].
Discussion
This analysis of a large, prospectively studied cohort of
patients with severe emphysema screened for enrollment
in a clinical trial of lung volume reduction surgery
makes several important observations about state anxi-
ety. We show that state anxiety was significantly and
independently associated with 1) shorter 6 MWD dis-
tance; 2) diminished maximum workload on cardiopul-
monary exercise testing; 3) poorer health-related quality
of life, and 4) more shortness of breath. It should be
Table 1 Characteristics of enrolled NETT patients used in this report* (n = 1828).
Age at evaluation (years; Mean ± SD) 66.7 ± 6.3
Gender 1134 (62%) Male
694 (38%) Female
Race/ethnic group 1727 (94%) Non-Hispanic white
73 (4%) Non-Hispanic black
28 (2%) Other
FEV1
% of predicted (Mean ± SD) 27.1 ± 7.5
L (Mean ± SD) 0.78 ± 0.25
DLCO
% of predicted (Mean ± SD) 28.2 ± 10.1
ml/min/mmHg STPD (Mean ± SD) 8.0 ± 3.2
Beck Depression Inventory (Mean ± SD) 9.5 ± 6.0
Spielberger Anxiety Inventory - State (Mean ± SD) 34.9 ± 10.9
6-Minute Walk Test (meters; Mean ± SD) 344.2 ± 105.8
Maximum Exercise Capacity (watts; Mean ± SD) 35.6 ± 21.9
St. George’s Respiratory Questionnaire - total score (Mean ± SD) 56.4 ± 13.1
UCSD Shortness of Breath Questionnaire (Mean ± SD) 64.9 ± 19.4
* Includes some patients who were not ultimately randomized to treatment. See Methods for additional details
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emphasized that our measure of anxiety evaluates a gen-
eral state of feeling anxious and does not indicate how
anxious patients actually felt during exercise testing.
Emotional distress experienced during exercise may be
even more strongly associated with performance out-
comes [37-39]. Nonetheless, our findings suggest that
anxiety may be a valid target for therapeutic interven-
tions in patients with severe emphysema.
A key feature of our report is the objective measure-
ment of physical functioning using well-validated phy-
siologic measures, which allows us to extend the
findings of other investigators who suggested greater
impairment in physical functioning and quality of life
with increasing levels of anxiety in COPD patients
[7,40-42]. Our results contrast with those of Borak et al.,
who reported no significant effect of anxiety on exercise
Table 2 Results of multiple linear regression analyses for 6 MWD, maximum exercise, quality of life, and shortness of
breath.
Model fit
B SE Beta p 95% Confidence Interval for B R2 p
6MWD
Age (years) -2.37 .37 -.14 <.001 [-3.09, -1.65]
Male Gender 45.04 4.78 .21 <.001 [35.67, 54.40]
FEV1% 3.39 .33 .25 <.001 [2.75, 4.03]
DLCO% 2.61 .23 .25 <.001 [2.15, 3.06]
Depression-M .26 .79 .01 .746 [-1.30, 1.81]
Depression-P -2.64 .85 -.08 .002 [-4.31, -.97]
Anxiety -.99 .24 -.10 <.001 [-1.45, -.52] .22 <.001
Max. exercise
Age (years) -.62 .07 -.18 <.001 [-.75, -.49]
Male Gender 20.44 .85 .45 <.001 [18.77, 22.11]
FEV1% 1.14 .06 .40 <.001 [1.03, 1.26]
DLCO% .50 .04 .23 <.001 [.42, .58]
Depression-M .21 .14 .03 .142 [-.07, .49]
Depression-P -.73 .15 -.11 <.001 [-1.02, -.43]
Anxiety -.10 .04 -.05 .017 [-.19, -.02] .43 <.001
Quality of life
Age (years) -.26 .04 -.13 <.001 [-.35, -.18]
Male Gender 1.18 .56 .04 .037 [.07, 2.29]
FEV1% -.10 .04 -.06 .012 [-.17, -.02]
DLCO% -.07 .03 -.05 .018 [.-12, -.01]
Depression-M .31 .09 .09 .001 [.12, .49]
Depression-P 1.34 .10 .33 <.001 [1.15, 1.54]
Anxiety .187 .03 .16 <.001 [.13, .24] .28 <.001
Shortness of Breath
Age (years) -.132 .07 -.04 .045 [-.26, -.01]
Male Gender -2.940 .85 -.07 .001 [-4.61, -1.27]
FEV1% -.345 .06 -.14 <.001 [-.46, -.23]
DLCO% -.285 .04 -.15 <.001 [-.37, -.20]
Depression-M .139 .14 .03 .331 [-.14, .42]
Depression-P 1.836 .15 .30 <.001 [1.54, 2.13]
Anxiety .206 .04 .12 <.001 [.12, .29] .24 <.001
Unstandardized regression coefficients (B), standard errors (SE), standardized coefficients (Beta), significance values (p), and 95% confidence intervals are shown
for each independent variable. Goodness-of-fit (R2) shown for each regression model. For each regression model, BDI depression was entered either as total score
or as two separate independent variables composed of the mood (Depression-M) or physical (Depression-P) BDI symptom items.
FEV1%: forced expiratory volume in 1 second, percent of predicted.
DLCO%: single-breath diffusing capacity of carbon monoxide, percent of predicted.
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performance [9], however the differences may relate
mostly to methodological and data analytical issues.
That study examined the effects of a number of psycho-
logical variables, including anxiety and depression, on
6 MWD in a group of 49 patients with moderate to
severe COPD, and concluded that they had no effect at
all on exercise performance. In their analyses, authors
entered up to 15 independent variables into a multiple
regression equation, with 6 MWD as the dependent
variable. With only 49 patients, this model may have
been underpowered to detect anything but very large
effects. In addition, the power to detect an effect of
anxiety was decreased further by the conversion of anxi-
ety to a categorical variable of low, moderate or high
based on subjects’ scores on a continuous measure of
anxiety. In contrast, our study analyzed anxiety as a con-
tinuous variable and, to our knowledge, utilized the lar-
gest sample size to date to examine the question.
Our results also contrast with those of Weaver and col-
leagues [43], who tested a causal model of factors affect-
ing self-reported physical, mental, and social functioning
including age, length of illness, FEV1, dyspnea, depres-
sion, anxiety, self-esteem, and exercise capacity, as mea-
sured by the 12-minute walk test in patients with COPD.
They found that anxiety was linked to exercise capacity,
but only through its association with depression and dys-
pnea. It is possible that the differences in findings
between these studies are due to the use of different mea-
sures of anxiety, depression, and dyspnea. In addition,
our subjects were a more homogenous group with more
severe COPD and an emphysematous phenotype.
Our analyses showed that depression, as measured by
the BDI total score, was significantly associated with
poorer exercise performance and worse health-related
quality of life scores. But, our results indicate that the
observed association between depression and other
patient variables was due to the somatic symptoms of
depression included on the BDI. These include, for
example, “I get tired more easily than I used to”, “It
takes an extra effort to get started at doing something”,
and “My appetite is not as good as it used to be.” It is
easy to see that these depression symptoms are also
likely to be indicators of COPD severity. Thus, it is diffi-
cult to conclude that the observed associations between
BDI total score and patient functioning were related to
depression per se, rather than items on the BDI that
served as another proxy for COPD severity. Future stu-
dies should use measures of depression that minimize
overlap with COPD symptoms.
Our analysis of the effect of gender on the association
between anxiety and functioning found an interaction
between gender and anxiety on quality of life reports.
For men, higher anxiety was associated worse health-
related quality of life, as measured by the SGRQ total
score. For female patients this association was much
weaker, although still statistically significant. This find-
ing is somewhat surprising given that greater emotional
distress and lower health satisfaction and quality of life
have been found for women with COPD in many
[44-47], but not all [48,49] studies. In our data also,
women reported greater symptoms of anxiety and
depression than did men. Nonetheless our finding sug-
gests that anxiety may impact men’s ratings of health-
related quality of life more than for woman. This inter-
action effect was not found for exercise performance or
shortness of breath, indicating that the gender difference
in the association between anxiety and quality of life is
not due to a greater adverse impact of dyspnea or
impaired physical functioning on quality of life for men.
However it may be that anxiety has a greater impact on
important activities and roles in men with COPD.
Future research could be designed to more specifically
study this potentially important phenomenon.
Several mechanisms, not mutually exclusive, may
explain the link between anxiety and functional impair-
ment in patients with COPD. First, anxiety may increase
disability in COPD by increasing vigilance for, and amplifi-
cation of, distressing respiratory sensations. The tendency
to misinterpret ambiguous or potentially threatening sti-
muli, a characteristic of many anxiety disorders, would
lead anxious COPD patients to avoid any activity that
might produce these sensations. Second, patients with
higher anxiety may be more emotionally sensitive to
unpleasant somatic sensations, which would to lead to
greater distress when these bodily cues are encountered.
In a recent population-based longitudinal study, anxiety
and depression were associated with the new onset of dys-
pnea, but not vice versa [50]. Third, longitudinal experi-
ence with COPD symptoms may generate fearful or
catastrophic beliefs about respiratory sensations, which, in
turn, provoke anxiety that limits engagement in physical
activity. Patients with COPD and panic disorder report
more fearful thoughts about, and avoidance of, unpleasant
somatic sensations than COPD patients without anxiety
[51]. Patients who endorse beliefs such as “dyspnea is
always a sign of danger”, or “activities that produce dys-
pnea make my COPD worse and should be avoided” are
more functionally impaired and report poorer quality of
life independent of COPD severity [52]. Near-death epi-
sodes, need for ventilatory support, and other illness
experiences could also influence the development of these
fearful beliefs and frightening thoughts.
Why anxiety is so much more common in COPD than
in the general population or in other disease states
remains unclear. Repetitive experiences with hypoxia
and hypercapnia might sensitize neural circuits that
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control fear responses, such as neurons in the amygdala
and locus ceruleus, to overreact to either subsequent
episodes of hypoxia and hypercapnia or to fearful per-
ceptions of conditioned stimuli such as the sensation of
breathlessness [53]. These reactions would again lead to
avoidance of physical activity and limit exercise perfor-
mance. In addition, a vicious circle may ensue, in which
dyspnea leads to anxiety, which produces a rapid, shal-
low breathing pattern, leading to air trapping and hyper-
inflation, creating further dyspnea and exercise
limitations [54]. Thus, anxiety in the context of COPD
may represent a ‘normal’ response to the anxiogenic
experience of repeated dyspnea, hypoxia, or hypercapnia;
or it may reflect the presence of a pre-morbid anxiety
problem that may become exacerbated in the presence
of COPD symptoms. Deciphering the relative contribu-
tions of these two pathways to anxiety will require long-
itudinal studies beginning in more mild stages of COPD.
Our findings suggest that screening for anxiety may be
important in patients with moderate to severe COPD.
Treating anxiety when present in patients with COPD
may not only reduce emotional distress, but also
improve physical functioning and overall quality of life.
Brief screening instruments have been validated for the
detection of anxiety in medical settings [55]. And, while
there are no published large randomized controlled stu-
dies of treatments for anxiety disorders in patients with
COPD, number of studies report decreased anxiety
symptoms in COPD with antidepressant therapy
[56-59], cognitive-behavioral therapy [60,61], or exercise
therapy, including pulmonary rehabilitation [11,62-66].
Our findings from our analysis of data from the
NETT have some limitations. As with all research
reports from treatment trials such as the NETT, the
most serious limitation is related to subject characteris-
tics influenced by study selection criteria and subject
self- selection. Subjects in this study had moderate to
severe emphysema. In addition, subjects who partici-
pated in the NETT were not current cigarette smokers
and had agreed to participate in a rigorous pulmonary
rehabilitation program. As a result, it is important to
note that our findings may not be generalizable to all
patients with COPD. Likewise, since only patients with
COPD were included (i.e., there was not a non-COPD
control group), our results are not generalizable to
other patient groups. Second, questionnaires were
administered prior to pulmonary rehabilitation and
treatment randomization. Thus, while the measures
were thus not influenced by the impact of rehabilita-
tion or treatment, it is possible that subjects may have
experienced heightened anxiety or mood symptoms in
anticipation of rehabilitation participation or treatment
assignment.
While the associations between state anxiety and exer-
cise performance found in our study were statistically
significant, the absolute effect sizes for anxiety were
modest. We found that a 10-point increase in state anxi-
ety score is associated with a mean decrease in 6 MWD
of 9 meters, a decrease in maximum exercise workload
of approximately 1 Watt, and an increase of approxi-
mately 2 points on the SGRQ and the UCSD SOBQ.
Published guidelines for the 6 MWD suggest 50 meters
change to indicate clinically significant changes in walk
distance [67]. For the SGRQ a change in 4 points is
used to indicate clinically important differences in
health-related quality of life [24]. However these guide-
lines were based on within-subject changes observed in
clinical trials, rather than between-subject differences in
cross-sectional studies. Nonetheless, using these figures
as a rough guide, a patient with a high state anxiety
score (2 SD above the mean or STAI = 57) in our sam-
ple would be expected to walk about 40 meters less on
the 6 MWD and score 9 points worse on the SGRQ
than a patient with low state anxiety (2 SD below the
mean, or STAI score = 13). Thus, while the effect of
anxiety on patients with COPD appears to be clinically
meaningful, the significance of our findings needs to be
further evaluated.
Conclusion
In summary, we found that state anxiety is associated
with worse functioning on measures of exercise perfor-
mance, health-related quality of life and shortness of
breath in patients with moderate to severe emphysema,
after accounting for the influence of demographic and
physiologic factors known to affect these outcomes. Our
results support the need for additional research into the
role of anxiety as an important source of functional
impairment and decreased quality of life in patients with
COPD. Future studies will need to examine the mechan-
isms by which anxiety impacts exercise performance.
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